Delivery of genetic medicines for muscular dystrophies

Yulia Chulanova, Dor Breier, Dan Peer

Research output: Contribution to journalReview articlepeer-review

Abstract

Muscular dystrophies are a group of heterogenic disorders characterized by progressive muscle weakness, the most common of them being Duchenne muscular dystrophy (DMD). Muscular dystrophies are caused by mutations in over 50 distinct genes, and many of them are caused by different genetic mechanisms. Currently, none of these diseases have a cure. However, in recent years, significant progress has been made to correct the underlying genetic cause. The clinical development of adeno-associated viral vector-based therapies has simultaneously produced excitement and disappointment in the research community due to the moderate effect, making it clear that new methods of muscle delivery have to be created. Herein, we review the main characteristics of major muscular dystrophies and outline various muscle-targeted delivery methods being explored for genetic medicines.

Original languageEnglish (US)
Article number101885
JournalCell Reports Medicine
Volume6
Issue number1
DOIs
StatePublished - Jan 21 2025

Keywords

  • adeno-associated virus
  • extracellular vesicles
  • gene delivery
  • gene editing
  • gene therapy
  • genetic medicines
  • lipid nanoparticle
  • muscular dystrophy
  • polymer nanoparticle

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Delivery of genetic medicines for muscular dystrophies'. Together they form a unique fingerprint.

Cite this